Search

Search Constraints

You searched for: Author/Creator Herrera, A.F.

Search Results

1. BET INHIBITOR RG6146, VENETOCLAX, AND RITUXIMAB IS A HIGHLY ACTIVE REGIMEN IN RELAPSED/REFRACTORY (R/R) DLBCL: INITIAL REPORT OF PHASE 1B SAFETY, BIOMARKER, AND RESPONSE DATA. (12th June 2019)

2. INTERIM RESULTS FROM a PHASE 1/2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA. (June 2017)

3. PET‐ADAPTED NIVOLUMAB +/‐ ICE AS INITIAL SALVAGE THERAPY IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA. (12th June 2019)

4. POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB OR OBINUTUZUMAB IN RELAPSED/REFRACTORY FL OR DLBCL: UPDATED RESULTS OF A PHASE 1B/2 STUDY. (June 2017)